What are the risks associated with testosterone replacement therapy compared to non‑medical anabolic androgenic steroid use?

Testosterone Replacement Therapy vs. Non-Medical Anabolic Steroid Use: Risk Profile

Testosterone replacement therapy (TRT) at physiologic doses carries substantially lower risks than non-medical anabolic-androgenic steroid (AAS) use, which involves supraphysiologic doses and polypharmacy that lead to severe cardiovascular events, persistent hypogonadism, and potentially fatal complications even after cessation.

Key Risk Distinction: Dose and Intent

The fundamental difference lies in dosing and monitoring. TRT aims to restore testosterone to normal physiologic levels (typically 300-1000 ng/dL) under medical supervision, while non-medical AAS use involves supraphysiologic doses—often 10-100 times higher—combined with multiple agents simultaneously 1, 2.

Risks of Medically-Supervised TRT

Cardiovascular Effects

• Minimal risk at physiologic doses: Pooled analysis of 2,415 patients showed no significant increase in cardiovascular events (Peto OR 1.22, CI 0.66-2.23) 3
• Lipid profile remains neutral when testosterone is maintained within physiologic range 4
• No evidence linking TRT to coronary artery disease at appropriate doses 4

Hematologic Complications

• Erythrocytosis is the most common complication, occurring in:
  • 2.8% with low-dose transdermal patches
  • 11.3-17.9% with gel preparations (dose-dependent)
  • 43.8% with intramuscular injections 4
• Risk increases with supraphysiologic levels and in patients with chronic obstructive pulmonary disease 4
• Critical monitoring point: Check hematocrit/hemoglobin regularly; intervene with dose reduction, withholding therapy, or phlebotomy if erythrocytosis develops 4

Prostate Effects

• Benign prostatic hyperplasia: Rare exacerbation despite prostate volume increases 4
• Prostate cancer: Theoretical risk remains unproven; no evidence that physiologic TRT causes cancer, though it may unmask occult disease 4
• Contraindicated in men with untreated prostate or breast cancer 5, 6

Reproductive Effects

• Testicular atrophy and infertility are common due to suppression of the hypothalamic-pituitary-gonadal axis 4
• This occurs even with TRT but is far more severe with AAS abuse

Other TRT Risks

• Sleep apnea exacerbation 4
• Gynecomastia (occasionally persists) 4, 5
• Acne and local skin reactions 4
• Fluid retention 4
• Edema risk in patients with pre-existing cardiac, renal, or hepatic disease 5

Catastrophic Risks of Non-Medical AAS Use

Cardiovascular Devastation

Non-medical AAS use causes severe, potentially irreversible cardiovascular damage:

• Anabolic steroid-induced cardiomyopathy (ASIC) 1
• Cardiac remodeling and dysfunction 2
• Fatal cardiovascular events occur even after prolonged abstinence: One case documented death from cardiovascular event more than one year after cessation despite normalized cardiac function 1
• Increased risk of myocardial infarction and stroke 2

Severe Endocrine Disruption

• Profound suppression of hypothalamic-pituitary-gonadal axis leading to severe hypogonadism 7, 2
• Recovery is heterogeneous and often incomplete: Endocrine parameters may normalize before semen parameters, but prolonged/high-dose exposure causes delayed or incomplete recovery in a clinically significant subset 2
• Risk of permanent primary hypogonadism: One documented case developed idiopathic primary hypogonadism requiring lifelong TRT after AAS cessation 1
• Severe oligozoospermia to azoospermia 2

Substance Dependence

AAS have unique addiction mechanisms:

• Development of AAS use disorder with specific withdrawal syndrome 1, 8
• Hormonal dysregulation drives tolerance and continued use despite harms 8
• Post-use hypogonadism creates physiologic dependence 8
• Muscle dysmorphia frequently co-occurs 1, 8

Multi-System Toxicity

• Hepatic injury, particularly with 17α-alkylated agents: hepatic adenomas, hepatocellular carcinoma, peliosis hepatis 5, 2
• Acute kidney injury through multiple mechanisms 9
• Severe polycythemia with prothrombotic changes 1, 2
• Tendon pathology 2
• Neuropsychiatric symptoms 2

Clinical Implications

For TRT Patients

Monitor hematocrit every 3-6 months, especially in first year and with injectable formulations. Transdermal preparations carry lower erythrocytosis risk than injections 4. Screen for sleep apnea, prostate symptoms, and cardiovascular risk factors. TRT does not substantially worsen lower urinary tract symptoms and may improve them 10.

For AAS Users

The risk profile is fundamentally different and far more severe. Even with cessation and "best practices" harm reduction, fatal outcomes occur 1. Management requires multidisciplinary care including psychiatry (for body dysmorphia and addiction), endocrinology (for hypogonadism management), and cardiology (for cardiovascular screening) 1, 8. Screen aggressively for cardiovascular complications, as they may be reversible if caught early but can persist fatally even after prolonged abstinence 1.

Critical Caveat

The persistent cardiovascular risk after AAS cessation cannot be overstated: documented fatal cardiovascular events occur more than one year after stopping non-medical use, despite apparent clinical recovery 1. This represents a qualitatively different risk than physiologic TRT.